Item 2.02 Results of Operations and Financial Condition. On January 13, 2021, Halozyme Therapeutics, Inc., a Delaware corporation ("Halozyme") presented at the annual JP Morgan Healthcare Conference to provide a corporate update on certain strategic programs and to provide financial guidance for 2021. The slides used by Halozyme in making the presentation contained information related to Halozyme's expected financial results for a completed fiscal period. A copy of the slides used by Halozyme is attached hereto as Exhibit 99.1.

Exhibit 99.1 is furnished under Item 2.02 of this report and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 7.01 Regulation FD Disclosure. The copy of the slides used by Halozyme in making the JP Morgan Healthcare Conference presentation attached hereto as Exhibit 99.1 is incorporated herein by reference and is expected to be used in subsequent presentations to interested parties, including analysts and stockholders.

This information is being furnished pursuant to Item 7.01 of this Report and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by Halozyme, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference. This Report will not be deemed an admission as to the materiality of any information in this Report that is being disclosed pursuant to Regulation FD.

Please refer to page 2 of the presentation attached hereto as Exhibit 99.1 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.




Item 9.01 Financial Statements and Exhibits.
Exhibits
Exhibit No.       Description

  99.1            Halozyme Therapeutics, Inc. corporate update presentation, dated January 13, 2021
104               Cover Page Interactive Data File (embedded within the Inline XBRL document )

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses